BiVictriX gets patent for its lead asset in Japan

The AIM-traded firm’s announcement came on the heels of its previous update on 23 August regarding the patent grant by the United States Patent and Trademark Office.

It said the newly granted patent further strengthened the protection of BVX001 and was part of its strategy to secure broad global protection for the groundbreaking anti-cancer therapeutic.

The patent claims were currently under prosecution in six additional jurisdictions worldwide.

“The approval of this patent in Japan, which follows swiftly after the granting of our patent in the US, puts BiVictriX in a strong intellectual property position in two key global markets,” said chief executive officer Tiffany Thorn.

“With plans to prosecute in a further six global jurisdictions, we are building strong protection for our lead therapeutic asset, at the broadest level, enhancing the value of BVX001 as we prepare for first in human studies and refine the optimal drug development and commercialisation strategy.”

At 1117 GMT, shares in BiVictriX Therapeutics were down 6.25% at 11.25p.

Reporting by Josh White for Sharecast.com.